ÂÜÀòÂÒÂ×

Daniel Peng is an experienced regulatory affairs professional currently serving as the Senior Director of Regulatory Affairs CMC at Checkpoint Therapeutics Inc since March 2022. Prior experience includes directing Global Regulatory Affairs – CMC Biologics at Merck and serving as Senior Principal Scientist at Shire's Drug Product Manufacturing Science & Technology group. Daniel has held significant roles at the FDA, including Quality Assessment Lead and Acting Team Leader, focusing on the scientific review of manufacturing processes for drug applications. A former Senior Formulation Scientist at AstraZeneca, Daniel has a solid foundation in formulation design and process optimization. Academic achievements include a Postdoctoral Fellowship in Industrial Pharmacy from the University of Tennessee and a Ph.D. in Pharmaceutics from West China University of Medical Sciences.